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OBJECTIVES: Chronic spontaneous (or idiopathic) urticaria (CSU/CIU) affects 
approximately 0.6% of Taiwanese population. However, little is known about its 
economic impacts in the healthcare system. This study aims to examine the 
costs of CSU/CIU-related treatment in National Health Insurance (NHI) program 
of Taiwan. METHODS: Patients who had at least two outpatient visits (primary/
secondary ICD-9-CM diagnosis code of 708.1, 708.8 or 708.9) with antihistamine 
prescription and occurred at least 42 days apart during 2011 were considered as the 
CSU/CIU cases from the NHI Research database(NHIRD). The cases were matched 
with controls in a 1:4 ratio by age, gender and residential areas from the 2011 NHI 
claims data files for 1-million beneficiaries who were representative of the popula-
tion of Taiwan in 2005. Differences in costs associated with outpatient care, inpatient 
care, emergency care, medical tests and drugs between CSU/CIU cases and their 
comparison groups were predicted by the two-part models and the generalized lin-
ear models. All analysis was stratified by the severity level of CSU/CIU and all costs 
were reported in 2012 New Taiwan dollars (US$1 = NT$30). RESULTS: There were 
145,700 CSU/CIU patients identified as the study cases based on above algorithm, 
of which 83.96% were mild CSU/CIU (dCSU), 15.79% were moderate CSU/CIU (mCSU) 
and 0.25% were severe CSU/CIU (sCSU). The case-comparison analysis showed that 
the NHI costs for patients with dCSU, mCSU and sCSU was 1.23 times, 1.43 times, 
and 1.93 times the costs of the matched controls, respectively. The annual total 
costs attributed to dCSU, mCSU and sCSU were NT$5,730, NT$9,168 and NT$20,522, 
respectively. Costs associated with outpatient care comprised the largest proportion 
of total costs for dCSU patients (60.0%) and for mCSU patients (57.5%). As for sCSU 
patients, the largest components of costs were medical tests (35.0%) and drugs 
(39.4%). CONCLUSIONS: CSU/CIU has substantially impact on direct medical costs 
in Taiwan. The costs increase remarkably with the severity of disease.
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OBJECTIVES: To calculate the costs of canalicular laceration (CL) repair at a tertiary 
academic eye care center based on setting and surgeon type. METHODS: A retro-
spective review of hospital records over a 10-year span of all primary CL repairs 
performed at a tertiary eye institution. Input variables included repair setting (minor 
procedure room; MPR vs. operating room; OR), surgeon type (oculoplastic surgeon, 
ophthalmologist, fellow, or resident), stent type (mini-Monoka vs. Crawford), and 
success rate (no epiphora/tearing down face, even with environmental stressors, 
at > 3 months after stent removal). Procedure-level data were used to inform prob-
abilities in a decision analytic model (TreeAge Pro). Costs inputs included supplies 
(institution acquisition prices for drugs and disposable equipment) and personnel 
(institution wages + 30% fringe benefits for surgeon, nurse, nurse anesthetist, anes-
thesiologist, and scheduler). Output of the model was cost per successful repair. 
Univariate sensitivity analyses were performed to test the impact of modifying 
base case inputs ± SD. RESULTS: The estimated cost per procedure was $US323 
in the MPR and $US589 in the OR. The overall success rate in the MPR was 37%, vs. 
88% in the OR (p< 0.0001). The ICER revealed the incremental cost of performing CL 
repair in the OR per success to be $521.56. Within each setting, cost effectiveness of 
oculoplastic surgeons dominated vs. the other surgeon types. Sensitivity analyses 
revealed OR costs to be most sensitive to nurse anesthetist and nurse time, whereas 
MPR costs were most sensitive to ophthalmologist and nurse time. CONCLUSIONS: 
While it was more costly to perform CL repair in the OR, success rates were much 
higher. In addition, success rates were optimal when performed by oculoplastic sur-
geons, suggesting that sub-specialty training maximizes patient outcome. Findings 
are limited to a single institution but call to question whether this procedure should 
be performed in a MPR.
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OBJECTIVES: The objective of this study is to evaluate the cost-effectiveness 
of aflibercept compared to ranibizumab and dexamethasone in the treatment 
of central retinal vein occlusion (CRVO) in Turkey. METHODS: A Markov model 
consisting of health states based on the number of letters read in 15 letter incre-
ments from legal blindness (< 35 letters) to 80+ letters with 30-year timeframe, 
was adapted to the Turkish local setting. Clinical inputs as transitions probabilities 
and incidences of adverse effects were mainly derived from the results of Phase 
III COPERNICUS and GALILEO trials. Economic inputs were based on the expert 
opinion addressing local treatment, monitoring and adverse event management 
algorithms. The primary endpoint was QALYs. Analyses were conducted from the 
Turkish Payer Social Security Institution perspective. All costs were calculated in 
Turkish Liras (TL) and converted to USD using TL/USD currency rate as 2,1 (mid-
2014). RESULTS: The total number of QALYs associated with aflibercept, ranibi-
zumab and dexamethasone were 17.926, 17.194 and 16.928 QALYs respectively; 
resulting in total of 0,101 and 0,368 more QALYs for the treatment with aflibercept 
OBJECTIVES: Equine recurrent uveitis (ERU) is the most common cause of blindness in 
horses world-wide. Several organisms have been associated with ERU, with leptospires 
being the most commonly reported agent. Irrespective of substantial treatment costs, 
the value of affected horses is progressively reduced as ocular involvements (unilateral 
or bilateral visual impairment or blindness) increase. This study aimed to estimate 
the number of horses affected by ERU in the U.S, and approximate the associated 
depreciation due to vision impairment. METHODS: The U.S. horse population size 
was estimated by market research. Published sources allowed the estimation of (1) the 
risk of ERU, (2) the associated visual impairments, accounting for breed differences, 
and (3) the loss of value in function of different ocular involvements and variable 
uses of a horse. Considering U.S. horse breeds and use distributions, the number of 
horses allocated to different levels of vision impairment and associated relative depre-
ciations were calculated. Average value of horses was derived from official sources, 
conservatively excluding very high-priced competition/race horses. RESULTS: It was 
estimated that 576,000 horses are currently affected by ERU in the U.S. Based on ret-
rospective studies, 198,513 and 104,269 of these horses are or are expected to become 
blind in one or both eyes during the next 11 years, respectively. From those horses being 
impaired but maintaining vision, 151,046 horses are unilaterally and 122,172 bilater-
ally affected. Depreciation in horses currently affected by ERU was conservatively 
calculated to $802,482,773. It was estimated that 70% of those losses are caused by 
leptospires. CONCLUSIONS: Approximately 576,000 horses are currently affected by 
ERU in the U.S., from which more than 300,000 horses will become blind in one or both 
eyes. ERU represents a substantial economic burden which conservatively calculates 
to more than $800 MM due to the loss of horse value, not considering treatment costs.
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OBJECTIVES: To estimate the cost of illness associated with diabetic macular edema 
(DME) in 13 countries, with a focus on diagnosis, treatment and cost of advanced 
disease. METHODS: A structured literature review to assess prevalence and cost of 
DME was conducted including Embase, Medline, government and professional asso-
ciation websites. Structured face-to-face or online interviews were conducted with 
378 ophthalmologists experienced in managing DME to determine rates of diagnosis, 
use of drug and laser treatments and frequency of follow-up and monitoring vis-
its. Countries were Belgium, Czech Republic, Finland, France, Germany, Ireland, the 
Netherlands, Poland, Portugal, Spain, Sweden, Switzerland and China. An excel model 
synthesizing data and estimated overall cost of illness was built; costs were converted 
to Euros at 2014 market rates. RESULTS: Across the 13 countries an estimated 5.3 
million people have DME; physicians estimated 32-68% (range between countries) of 
DME patients are undiagnosed, a total of 3.1m people. Annual medical cost of DME 
was estimated to be € 1.2bn, median medical cost per patient was € 918, range from € 46 
(China) to € 4,858 (Switzerland). Productivity loss due to poor vision in DME patients 
costs € 4.7bn, 71% of the total cost of illness. Other cost components were laser and 
drug treatments (mean across countries 17.9%, range 1.4-38.9%), follow-up visits (5.8%, 
2.6-33.9%) and monitoring visits (2.9%, 0.3-15.9%). Diagnosis accounted for 0.3% of 
the total cost (range 0.1-0.9%). Some cost components could not be reliably estimated 
for all countries. CONCLUSIONS: Considerable variation was identified in screening, 
diagnosis and treatment between countries. Despite the availability of effective thera-
pies, physicians reported that current practice fails to identify a substantial proportion 
of patients with DME. Poor vision due to DME results in economic loss that is much 
larger than current spending on therapy. Limitations include use of expert opinion 
and incomplete data; results may not be generalizable outside the countries studied.
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OBJECTIVES: Describing the cost of care for glaucoma patients will lead to a better 
understanding of the disease impact on the healthcare system. Few studies have 
determined healthcare costs associated with glaucoma patients, and even fewer 
examined a commercially insured population. This study sought to characterize 
and compare the glaucoma specific costs and overall healthcare costs before and 
after diagnosis. METHODS: We analyzed a large US commercial claims database to 
identify patients 18 years and older with an initial diagnosis of open-angle glaucoma 
occurring in 2011. Patients with two separate occurrences of open-angle glaucoma 
codes (ICD-9 365.10 or 365.11) were included. Patients were excluded for presence 
of a glaucoma code in the 12 months before their initial diagnosis, other types of 
glaucoma (i.e. angle-closure glaucoma), or other possible causes of vision loss (i.e.: 
cataracts). Outcomes of interest were glaucoma specific and overall healthcare costs 
for the 12-months before (baseline) and 12-months after (follow-up) initial diagnosis. 
Costs consisted of inpatient stays, emergency department visits, general and vision 
related office visits, glaucoma diagnostic tests, glaucoma surgeries, and medica-
tions. Paired t-tests were used to compare baseline and follow-up costs. RESULTS: 
8,575 patients were identified as having newly diagnosed glaucoma in 2011. Mean 
glaucoma specific baseline costs were $107 (95% CI: $102, $112) and follow-up 
costs were $487 (95% CI: $475, $498); resulting in a 4.6-fold increase from baseline 
(p ≤ 0.001). 41% of follow-up glaucoma costs were due to glaucoma medications. 
Mean overall healthcare costs at baseline were $5,405 (95% CI: $5,122, $5,688) and at 
follow-up were $7,106 (95% CI: $6,677, $7,534); resulting in a 1.3-fold increase from 
baseline (p ≤ 0.001). 23.2% of follow-up total healthcare costs were due to medica-
tions. CONCLUSIONS: Glaucoma specific and overall healthcare costs significantly 
increase after glaucoma diagnosis for patients who are commercially insured.
